Corcept Therapeutics Incorporated (CORT)
| Previous close | 22.66 |
| Open | 22.60 |
| Bid | 22.88 x 100 |
| Ask | 23.00 x 100 |
| Day's range | 22.56 - 23.03 |
| 52-week range | 20.87 - 34.28 |
| Volume | |
| Avg. volume | 1,209,617 |
| Market cap | 2.383B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 24.41 |
| EPS (TTM) | 0.94 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.80 |
ZacksCorcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ZacksCorcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
GlobeNewswireCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patien
